[go: up one dir, main page]

BRPI0416272A - fprl1 receptor uses, and compounds, prophylactic use of compounds, screening methods for a compound capable of affecting one or more activities of a fprl1 receptor, treating or preventing inflammation, identifying a vasodilation inducing compound, to antagonism of a vasoconstructive response to a leukotriene sulfidopeptide in an individual, and to stimulation of cell proliferation in an individual, and, compound - Google Patents

fprl1 receptor uses, and compounds, prophylactic use of compounds, screening methods for a compound capable of affecting one or more activities of a fprl1 receptor, treating or preventing inflammation, identifying a vasodilation inducing compound, to antagonism of a vasoconstructive response to a leukotriene sulfidopeptide in an individual, and to stimulation of cell proliferation in an individual, and, compound

Info

Publication number
BRPI0416272A
BRPI0416272A BRPI0416272-2A BRPI0416272A BRPI0416272A BR PI0416272 A BRPI0416272 A BR PI0416272A BR PI0416272 A BRPI0416272 A BR PI0416272A BR PI0416272 A BRPI0416272 A BR PI0416272A
Authority
BR
Brazil
Prior art keywords
compounds
compound
individual
fprl1
fprl1 receptor
Prior art date
Application number
BRPI0416272-2A
Other languages
Portuguese (pt)
Inventor
Norman Nash
Audra L Scully
Luis Gardell
Roger Olsson
Magnus Gustafsson
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of BRPI0416272A publication Critical patent/BRPI0416272A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ceramic Engineering (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Structural Engineering (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)

Abstract

"USOS DO RECEPTOR FPRL1, E DE COMPOSTOS, USO PROFILáTICO DE COMPOSTOS MéTODOS DE TRIAGEM PARA UM COMPOSTO CAPAZ DE AFETAR UMA OU MAIS ATIVIDADES DE UM RECEPTOR FPRL1, DE TRATAMENTO OU PREVENçãO DE INFLAMAçãO, DE IDENTIFICAçãO DE UM COMPOSTO, DE INDUçãO DE VASODILATAçãO, PARA ANTAGONISMO DE UMA RESPOSTA VASOCONSTRITIVA A UM SULFIDOPEPTìDEO LEUCOTRIENO EM UM INDIVìDUO, E PARA ESTIMULAçãO DE PROLIFERAçãO CELULAR EM UM INDIVìDUO, E, COMPOSTO". São aqui descritos compostos que seletivamente ativam o receptor FPRL1. São adicionalmente descritos métodos de alívio das respostas inflamatórias pela regulação de etapas chave em tráfego de leucócitos e na prevenção de dano de tecido mediado por neutrófilo pela administração a um indivíduo de uma quantidade terapeuticamente efetiva de compostos aqui descritos. Além disso, são proporcionados métodos de modulação, ou especificamente de agonismo de receptor FPRL1 pela administração de uma quantidade terapeuticamente efetiva de compostos aqui descritos."USES OF THE FPRL1 RECEIVER, AND COMPOUNDS, PROPHILATIC USE OF COMPOUNDS Screening Methods for a Compound Able to Affect One or More Activities of an FPRL1 RECEIVER, TREATMENT OR PREVENTION OF INFLAMMATION, IDENTIFICATION, INDUCTING, IDODING FOR ANTAGONISM OF A VASOCONSTRITIVE RESPONSE TO A LEUCOTRIENE SULFIDOPEPTIDE IN AN INDIVIDUAL, AND FOR CELL PROLIFERATION STIMULATION IN AN INDIVIDUAL ". Described herein are compounds that selectively activate the FPRL1 receptor. Further described are methods of alleviating inflammatory responses by regulating key steps in leukocyte trafficking and preventing neutrophil-mediated tissue damage by administering to a subject a therapeutically effective amount of compounds described herein. In addition, methods of modulating, or specifically, FPRL1 receptor agonism by providing a therapeutically effective amount of compounds described herein are provided.

BRPI0416272-2A 2003-11-07 2004-11-04 fprl1 receptor uses, and compounds, prophylactic use of compounds, screening methods for a compound capable of affecting one or more activities of a fprl1 receptor, treating or preventing inflammation, identifying a vasodilation inducing compound, to antagonism of a vasoconstructive response to a leukotriene sulfidopeptide in an individual, and to stimulation of cell proliferation in an individual, and, compound BRPI0416272A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51847603P 2003-11-07 2003-11-07
US51908503P 2003-11-10 2003-11-10
US59292604P 2004-07-30 2004-07-30
PCT/US2004/036952 WO2005047899A2 (en) 2003-11-07 2004-11-04 Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation

Publications (1)

Publication Number Publication Date
BRPI0416272A true BRPI0416272A (en) 2007-01-09

Family

ID=34595924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416272-2A BRPI0416272A (en) 2003-11-07 2004-11-04 fprl1 receptor uses, and compounds, prophylactic use of compounds, screening methods for a compound capable of affecting one or more activities of a fprl1 receptor, treating or preventing inflammation, identifying a vasodilation inducing compound, to antagonism of a vasoconstructive response to a leukotriene sulfidopeptide in an individual, and to stimulation of cell proliferation in an individual, and, compound

Country Status (7)

Country Link
EP (1) EP1692502A2 (en)
JP (1) JP2007516434A (en)
KR (1) KR20060130064A (en)
AU (1) AU2004290368A1 (en)
BR (1) BRPI0416272A (en)
CA (1) CA2544983A1 (en)
WO (1) WO2005047899A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198912B2 (en) 2001-09-07 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding a human G-protein coupled receptor, HGPRBMY39
US20100291089A1 (en) * 2005-07-07 2010-11-18 Postech Academy-Industry Foundation Ligand of regulating immune response, and use thereof in treating an immune response-related disease
AR069650A1 (en) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF AMINOPIRAZOL AS NON-PEPTIDIC AGONISTS OF THE HUMAN ALX RECEPTOR
EP2225231B1 (en) 2007-12-18 2011-08-17 Actelion Pharmaceuticals Ltd. Aminotriazole derivatives as alx agonists
PT2432760E (en) * 2009-05-18 2013-10-21 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
EP2440555B1 (en) 2009-06-09 2016-05-18 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
CN102803237B (en) 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 Oxazole and thiazole derivatives as alx receptor agonists
KR101905927B1 (en) 2010-11-17 2018-10-08 이도르시아 파마슈티컬스 리미티드 Bridged spiro[2.4]heptane ester derivatives
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
JP5923108B2 (en) 2010-12-07 2016-05-24 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Hydroxylated aminotriazole derivatives as ALX receptor agonists
AU2011340146B2 (en) 2010-12-07 2016-05-19 Idorsia Pharmaceuticals Ltd Oxazolyl-methylether derivatives as ALX receptor agonists
AU2012214265A1 (en) * 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
ES2820714T3 (en) 2011-10-26 2021-04-22 Allergan Inc Substituted N-urea amino acid amide derivatives as modulators of formylated peptide receptor 1 (FPRL-1) receptor
EP2597160B1 (en) 2011-11-23 2015-09-23 Universita' Degli Studi "G. d'Annunzio" Chieti-Pescara Screening tool for anti-inflammatory drug discovery comprising the FPR2/ALX gene promoter
TW201348219A (en) 2012-05-16 2013-12-01 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
MA37618B1 (en) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Fluor [2.4] heptane fluorinated bridged derivatives as alx receptor agonists
EP2964213B1 (en) 2013-03-06 2020-11-04 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
WO2014204229A2 (en) * 2013-06-21 2014-12-24 성균관대학교산학협력단 Pharmaceutical composition for preventing or treating rheumatoid arthritis, comprising peptide as active ingredient
AR096686A1 (en) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd DERIVATIVES OF ESPIRO [2.4] HEPTANO BRIDGES SUBSTITUTED WITH DIFLUOROETIL-OXAZOL AS AGONISTS OF THE ALX RECEIVER
CN105377814B (en) * 2013-07-16 2018-04-03 阿勒根公司 Derivatives of N-urea-substituted amino acids as formyl peptide receptor modulators
JP6330038B2 (en) 2013-07-18 2018-05-23 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Piperazine-substituted cross-linked spiro [2.4] heptane derivatives as ALX receptor agonists
AR097279A1 (en) * 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS
MY179516A (en) 2013-11-28 2020-11-09 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
ES2788700T3 (en) 2014-05-21 2020-10-22 Allergan Inc Imidazole derivatives as formylated peptide receptor modulators
WO2016189876A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
KR101731303B1 (en) 2015-06-11 2017-05-02 가톨릭대학교 산학협력단 Screening method of interleukin-1beta inhibitors
CA3092927A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
IT202100004964A1 (en) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro FPR2 RECEPTOR AGONISTS (FORMYL PEPTIDE RECEPTOR 2) AND THEIR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031261A2 (en) * 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
CA2399032A1 (en) * 2000-02-04 2001-08-09 The Government Of The United States Of America Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
WO2003074069A2 (en) * 2002-03-07 2003-09-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
AU2003242340A1 (en) * 2002-06-14 2003-12-31 Takeda Pharmaceutical Company Limited Novel screening method
US20060141460A1 (en) * 2002-09-19 2006-06-29 Astrazeneca A B Assays for fprl-1 ligands
WO2005024057A1 (en) * 2003-09-10 2005-03-17 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell

Also Published As

Publication number Publication date
AU2004290368A1 (en) 2005-05-26
WO2005047899A3 (en) 2006-03-30
EP1692502A2 (en) 2006-08-23
JP2007516434A (en) 2007-06-21
CA2544983A1 (en) 2005-05-26
KR20060130064A (en) 2006-12-18
WO2005047899A2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0416272A (en) fprl1 receptor uses, and compounds, prophylactic use of compounds, screening methods for a compound capable of affecting one or more activities of a fprl1 receptor, treating or preventing inflammation, identifying a vasodilation inducing compound, to antagonism of a vasoconstructive response to a leukotriene sulfidopeptide in an individual, and to stimulation of cell proliferation in an individual, and, compound
GB9807639D0 (en) Anti-inflammatory agents
BRPI0409919A (en) combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cell cells, or angiogenesis
WO2004096148A3 (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
BR0314603A (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
TR200003650T2 (en) ß2-adrenergic receptor agonists
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DK1392131T3 (en) Skin Diet Feeds for Pets
BR0114978A (en) Compositions and methods that are useful in treating inflammatory, metabolic, and proliferative cell conditions or diseases.
BR0316296A (en) Lapacone compounds and their methods of use
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
BR0208675A (en) Immunotherapeutic combination for immunotherapy of ganglioside overexpressing tumors, use thereof and method for controlling the growth and / or proliferation of ganglioside overexpressing tumor cells
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
ATE510553T1 (en) BETA-2-GLYCOPROTEIN 1 AS ANGIOGENESIS INHIBITOR
FR2768622B1 (en) Rosacea extract as antagonist of bradykinin
NO963029L (en) Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells
Krause et al. UV radiation and cancer prevention: what is the evidence?
AR044452A1 (en) COMBINATION OF A P2X7 RECEIVER ANTAGONIST AND AN ALFA TUMOR NECROSIS FACTOR INHIBITOR
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
NO20012634L (en) New cancer treatments
SI1572182T1 (en) Composition for the treatment of gastrointestinal disorders
AR039803A1 (en) PROTEINS 1 AND 2 RELATED TO THE LDL RECEPTOR AND TREATMENT OF BONE OR CARTILAGO DISORDERS
ATE252896T1 (en) ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN AND ALKYL-PCDFS
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired